CEVEC Pharmaceuticals GmbH (CEVEC) announced the signing of a license agreement with Biogen Inc. for the use of CEVEC's proprietary ELEVECTA(R) Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Under the terms of the agreement, CEVEC grants Biogen a non-exclusive license for CEVEC's ELEVECTA(R) Technology. The deal will afford Biogen the rights to use the technology across their portfolio of gene therapy products. Under the license, CEVEC is eligible for technology access and milestone fees, including clinical development and commercial milestones, as well as royalties on net sales of products.